Fungal keratitis
Conditions
Interventions
experimental group:1% voriconazole eye drops
control group :Natamycin eye drops
Sponsors
Shenyang Sinqi Eye Hospital Co., Ltd
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-65 years old, regardless of gender; 2. Patients with typical history, symptoms and signs of fungal keratitis, 3 points <= eye score <= 8 points; 3. Patients identified as fungal infection by laboratory examination (fungal hyphae can be seen by corneal scraping microscopy, fungal hyphae can be seen by confocal microscopy, and any one of the two items can be positive); 4. The subjects did not receive antifungal drug treatment; 5. Patients who voluntarily participated in the trial and signed the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with the longest diameter line 6mm; patients with impending or existing corneal perforation and prominent posterior elastic layer; 2. Patients with bacterial infection were found by corneal scraping; 3. Patients with acute and chronic dacryocystitis; 4. Patients with dystrophic corneal ulcer and incomplete eyelid closure; 5. Patients who need to use steroid hormone or other immunosuppressants locally or in the whole body; 6. Patients with monocular or monocular vision; 7. Patients with corneal ulcer in both eyes; 8. Patients who are allergic to the drugs used in this study; 9. Patients with immune system diseases, cardiopulmonary insufficiency, liver and kidney dysfunction, and diabetes history; 10. The researcher judges the patients with abnormal laboratory examination indexes and clinical significance; 11. Patients with corneal surgery history; 12. Pregnancy (defined as positive pregnancy test), lactating women or patients with family planning within the past six months; 13. Patients who have participated in other clinical trials in the past 3 months; 14. Patients who are not considered suitable for the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effective rate of clinical treatment at the 12th week;Changes of ocular score relative to baseline at each follow-up point; | — |
Secondary
| Measure | Time frame |
|---|---|
| Effective rate of clinical treatment at the fourth, sixth and eighth week;Best corrected vision;Intraocular pressure;routine blood test;Hepatorenal function;Urine routine + microscopic examination of urine sediment;Urinary pregnancy; | — |
Countries
China
Contacts
Public ContactXiaonan Sun
Shenyang Xingqi Eye Hospital Co., Ltd
Outcome results
None listed